Interventions of Interest
For questions please contact [email protected].
- oveporexton (Takeda Pharmaceutical Co., Ltd.)
Narcolepsy
An assessment of oveporexton
Public Meeting
May 2026
Assessment Status
Closed
Main Review
May 14, 2026
Midwest CEPAC
The Midwest CEPAC’s 2026 public meeting on treatment for narcolepsy
ICER STAKEHOLDER OUTREACH AND PUBLIC COMMENTERS LIST
ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.
The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review.
- Avadel Pharmaceuticals PLC
- Day4NAPS
- Harmony Biosciences
- Jazz Pharmaceuticals
- Narcolepsy Network
- NORD
- Project Sleep
- Takeda Pharmaceutical Co. Ltd
- Wake Up Narcolepsy
To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.
None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.
Related Assessments & Policy Papers.
01/23/2026
Model Analysis Plan
Please find the model analysis plan here: https://osf.io/knqrg/files/4cmbj
03/12/2026
Draft Evidence Report
03/11/2026 - 04/07/2026
Public Comments on Draft Evidence Report
06/08/2026
Public Comments
Closed